Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Buy
56
GILD Quote, Financials, Valuation and Earnings
Last price:
$124.27
Seasonality move
:
8.84%
Day range:
$121.00 - $126.27
52-week range:
$88.57 - $128.70
Dividend yield:
2.54%
P/E ratio:
19.25x
P/S ratio:
5.38x
P/B ratio:
7.16x
Volume:
24.4M
Avg. volume:
7.7M
1-year change:
36.45%
Market cap:
$154.2B
Revenue:
$28.7B
EPS (TTM):
$6.46
Analysts' Opinion
-
Consensus RatingGilead Sciences, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 16 Buy ratings, 8 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $132.38, Gilead Sciences, Inc. has an estimated upside of 6.51% from its current price of $124.29.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $105.00 representing 15.52% downside risk from its current price of $124.29.
Fair Value
-
According to the consensus of 24 analysts, Gilead Sciences, Inc. has 6.51% upside to fair value with a price target of $132.38 per share.
GILD vs. S&P 500
-
Over the past 5 trading days, Gilead Sciences, Inc. has overperformed the S&P 500 by 3.8% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Gilead Sciences, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Gilead Sciences, Inc. has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Gilead Sciences, Inc. reported revenues of $7.8B.
Earnings Growth
-
Gilead Sciences, Inc. has grown year-over-year earnings for 4 quarters straight. In the most recent quarter Gilead Sciences, Inc. reported earnings per share of $2.43.
Enterprise value:
169.9B
EV / Invested capital:
3.66x
Price / LTM sales:
5.38x
EV / EBIT:
14.99x
EV / Revenue:
5.85x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
18.54x
Price / Operating cash flow:
17.05x
Enterprise value / EBITDA:
12.05x
Gross Profit (TTM):
$22.9B
Return On Assets:
14.27%
Net Income Margin (TTM):
27.91%
Return On Equity:
41.48%
Return On Invested Capital:
18.17%
Operating Margin:
45.34%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $27.3B | $28.3B | $29.1B | $7.5B | $7.8B | |
| Gross Profit | $21.9B | $22B | $22.9B | $6B | $6.2B | |
| Operating Income | $9.5B | $10.6B | $11.3B | $3.2B | $3.5B | |
| EBITDA | $12.1B | $13.3B | $14.1B | $3.9B | $4.2B | |
| Diluted EPS | $4.66 | $0.09 | $6.46 | $1.00 | $2.43 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $14B | $13.6B | $16B | $14.8B | $17.9B | |
| Total Assets | $67.1B | $62.6B | $62.4B | $54.5B | $58.5B | |
| Current Liabilities | $10.2B | $10.4B | $11.9B | $11.7B | $12.3B | |
| Total Liabilities | $45.6B | $41.5B | $40.1B | $36.1B | $37.1B | |
| Total Equity | $21.5B | $21.1B | $22.2B | $18.4B | $21.5B | |
| Total Debt | $27.7B | $25.2B | $25B | $23.2B | $24.9B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $8.4B | $10B | $9.7B | $4.3B | $4.1B | |
| Cash From Investing | -$1.9B | -$4B | -$3.2B | -$710M | -$427M | |
| Cash From Financing | -$5.6B | -$6.8B | -$4.2B | -$1.4B | -$1.5B | |
| Free Cash Flow | $7.9B | $9.4B | $9.2B | $4.2B | $4B | |
GILD
Sector
Market Cap
$154.2B
$27.9M
Price % of 52-Week High
96.57%
51.04%
Dividend Yield
2.54%
0%
Shareholder Yield
3.68%
-1.49%
1-Year Price Total Return
36.45%
-16.66%
Beta (5-Year)
0.318
0.516
Dividend yield:
2.54%
Annualized payout:
$3.08
Payout ratio:
32.46%
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$121.33
200-day SMA
Buy
Level
$113.35
Bollinger Bands (100)
Buy
Level
113.6 - 123.1
Chaikin Money Flow
Buy
Level
2.1B
20-day SMA
Buy
Level
$123.03
Relative Strength Index (RSI14)
Buy
Level
55.13
ADX Line
Buy
Level
16.46
Williams %R
Neutral
Level
-24.4435
50-day SMA
Buy
Level
$122.15
MACD (12, 26)
Sell
Level
-0.30
25-day Aroon Oscillator
Sell
Level
-68
On Balance Volume
Neutral
Level
4.8B
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.2396)
Buy
CA Score
(Annual)
Level (-0.1831)
Buy
Beneish M-Score
(Annual)
Level (-3.4119)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (5.317)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
Stock Forecast FAQ
In the current month, GILD has received 16 Buy ratings 8 Hold ratings, and 0 Sell ratings. The GILD average analyst price target in the past 3 months is $132.38.
-
Where Will Gilead Sciences, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Gilead Sciences, Inc. share price will rise to $132.38 per share over the next 12 months.
-
What Do Analysts Say About Gilead Sciences, Inc.?
Analysts are divided on their view about Gilead Sciences, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Gilead Sciences, Inc. is a Sell and believe this share price will drop from its current level to $105.00.
-
What Is Gilead Sciences, Inc.'s Price Target?
The price target for Gilead Sciences, Inc. over the next 1-year time period is forecast to be $132.38 according to 24 Wall Street analysts, 16 of them rate the stock a Buy, 0 rate the stock a Sell, and 8 analysts rate the stock a Hold.
-
Is GILD A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Gilead Sciences, Inc. is a Buy. 16 of 24 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of GILD?
You can purchase shares of Gilead Sciences, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Gilead Sciences, Inc. shares.
-
What Is The Gilead Sciences, Inc. Share Price Today?
Gilead Sciences, Inc. was last trading at $124.27 per share. This represents the most recent stock quote for Gilead Sciences, Inc.. Yesterday, Gilead Sciences, Inc. closed at $124.29 per share.
-
How To Buy Gilead Sciences, Inc. Stock Online?
In order to purchase Gilead Sciences, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get GILD Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
GILD
Sector
P/E ratio
19.25x
23.85x
PEG ratio
0.00x
-0.01x
P/B ratio
7.16x
1.81x
Price / LTM sales
5.38x
1.58x
Growth Metrics
GILD
Sector
Revenue growth
3.36%
4.62%
Earnings growth
142.22%
10.5%
Revenue (5-year growth)
5.18%
6.5%
Earnings forecast
$2.14
-$0.21
Profitability
GILD
Sector
Profitability FY 2024
$22.5B
$3.6M
Return on invested capital
18.17%
-31.87%
Return on assets
14.27%
-28.18%
Return on equity
41.48%
-37.63%
Earnings Date
Last Earnings Date
Oct
30
Next Earnings Date
Feb
10
Estimated Next Earnings Date
Jan
29
Balance Sheet
GILD
Sector
Total cash
$9.2B
$26.4M
Short term investments
$1.6B
$25.7M
Total assets
$59B
$76.9M
Long term debt
$24.9B
$3.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
